Stock KPRX KIORA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.47 USD -2.08% Intraday chart for Kiora Pharmaceuticals, Inc. -4.14% -10.03%
Mar. 25 Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 09 HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating MT

Evolution of the average Target Price on Kiora Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ef3c9980623708674937ec2450c3.Ow4Dlz1VcB1S8Ui0MZmKS8yj7PBiDhwxEsim8tAwlhY.VVpTwk9nR287iSXRW83_Zp7WpaFUf0h2Jrj5tZlJzFJXfXHPfC85azCaOw~51d7e17d0e2c983280da4147436b7910

Analyst Recommendations on Kiora Pharmaceuticals, Inc.

HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating MT
HC Wainwright Adjusts Kiora Pharmaceuticals' Price Target to $3.50 From $2, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $7, Keeps Buy Rating MT
HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating MT
Maxim Upgrades Kiora Pharmaceuticals to Buy From Hold, Price Target is $12 MT
Ladenburg Thalmann Reiterates Kiora Pharmaceuticals at Buy With $119 Price Target MT
HC Wainwright Reiterates Kiora Pharmaceuticals at Buy With $10 Price Target MT
Ladenburg Thalmann Initiates Kiora Pharmaceuticals at Buy With $6.50 Price Target MT
Maxim Group Downgrades Kiora Pharmaceuticals to Hold From Buy MT
HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2.50 From $3, Reiterates Buy Rating MT
HC Wainwright Adjusts Kiora Pharmaceuticals Price Target to $3 From $5, Maintains Buy Rating MT
Maxim Starts Kiora Pharmaceuticals at Buy With $2.50 Price Target MT
EYEGATE PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Eyegate Pharmaceuticals to $11 From $14, Maintains Buy Rating MT
EYEGATE PHARMACEUTICALS : Alliance Global Securities Adjusts Eyegate Pharmaceuticals PT to $10.75 From $10.25, Maintains Buy Rating MT
EYEGATE PHARMACEUTICALS : Alliance Global Partners Adjusts Eyegate Pharmaceuticals PT $10.25 From $16.75, Maintains Buy Rating MT
EYEGATE PHARMACEUTICALS : HC Wainwright Adjusts Eyegate Pharmaceuticals' Price Target to $14 From $10, Keeps at Buy MT
EYEGATE PHARMACEUTICALS : Alliance Global Partners Adjusts Eyegate Pharmaceuticals PT to $15.50 From $9.50, Maintains Buy Rating MT
EYEGATE PHARMACEUTICALS : HC Wainwright Adjusts Eyegate Pharmaceuticals' Price Target to $10 From $12, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.47 USD
Average target price
3.667 USD
Spread / Average Target
+680.14%
High Price Target
6 USD
Spread / Highest target
+1,176.60%
Low Price Target
2 USD
Spread / Lowest Target
+325.53%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kiora Pharmaceuticals, Inc.

HC Wainwright
Maxim
Ladenburg Thalmann
Alliance Global Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. KPRX Stock
  4. Consensus Kiora Pharmaceuticals, Inc.